Naval G. Daver

Oncology

1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 611 publications

Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.

Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.

Journal: Expert review of hematology

Published: August 19, 2026

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Journal: Leukemia & lymphoma

Published: July 26, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

Microclone with megaimpact.

Microclone with megaimpact.

Journal: Blood

Published: July 22, 2026

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 13, 2026

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)

Published: July 11, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Journal: Haematologica

Published: May 04, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

Journal: Human pathology

Published: April 20, 2026

Showing 1-12 of 611

Last Updated: 09/26/2026